Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158228 | 0.86 | KDM5A (0.56) | MAP3K5ALDH1A1KDM5AKDM5BKDM4E | |
| SCHEMBL20856777 | 0.82 | FEN1 (0.43) | MAP3K5ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL5113224 | 0.79 | PARP15 (0.48) | CSF1RMAP3K5ALDH1A1MEN1KMT2A | |
| SCHEMBL27703596 | 0.79 | PDPK1 (0.46) | ALDH1A1TDP1KDM4EFEN1 | |
| SCHEMBL14208429 | 0.77 | MEN1 (0.54) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL1061379 | 0.76 | KDM4E (0.64) | CSF1RMAP3K5ALDH1A1MEN1KMT2A | |
| SCHEMBL20856796 | 0.75 | KMT2A (0.46) | CSF1RMAP3K5ALDH1A1MEN1KMT2A | |
| SCHEMBL5104175 | 0.75 | CSF1R (0.47) | CSF1RMAP3K5ALDH1A1MEN1KMT2A | |
| SCHEMBL13739817 | 0.74 | CSF1R (0.52) | CSF1RMAP3K5ALDH1A1MEN1KMT2A | |
| SCHEMBL13295306 | 0.74 | CSF1R (0.58) | CSF1RALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365200-B2 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1861407-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS | 2006-10-12 | — | — | US | disclosed |
| WO-2006102191-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | MIF, MMP12, MSR1 | CSF1R 5/4885MAP3K5 2132/4885ALDH1A1 3434/4885 |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | CSF1R 214/4885MAP3K5 3577/4885ALDH1A1 2365/4885 |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | MIF, MMP12, MSR1 | CSF1R 5/4885MAP3K5 2132/4885ALDH1A1 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.